Neurocrine Biosciences (NBIX) Shares Outstanding (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Shares Outstanding (Entity) of $101.6 million for Q2 2026, up 2.63% year-over-year from $99.0 million in Q2 2025, and up 0.99% on a QoQ basis from $100.6 million in Q1 2026.
Neurocrine Biosciences (NBIX) Shares Outstanding (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $101.6 million in Q2 2026.
- Shares Outstanding (Entity) for Q2 2026 came in at $101.6 million, up 2.63% year-over-year; the trailing twelve-month figure through Jun 2026 was $101.6 million (up 2.63% YoY), and the FY2025 annual result was $100.1 million, up 0.7% from the prior year.
- Shares Outstanding (Entity) rose to $101.6 million in Q2 2026, from $100.6 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $101.6 million in Q2 2026 and troughed at $95.5 million in Q1 2022.
- A 5-year average of $98.8 million and a median of $99.0 million in 2025 frame the typical range for Shares Outstanding (Entity).
- The widest annual swing landed in 2024, when Shares Outstanding (Entity) advanced 3.38%; it then retreated 1.88% in 2025.
- A 5-year view of Shares Outstanding (Entity) shows it stood at $96.5 million in 2022, then advanced by 2.28% to $98.7 million in 2023, then rose by 0.71% to $99.4 million in 2024, then advanced by 0.7% to $100.1 million in 2025, then grew by 1.5% to $101.6 million in 2026.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $101.6 million in Q2 2026, $100.6 million in Q1 2026, and $100.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 832.44 Mn |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | 167.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 101.00 Mn |
| Mar 31, 2026 | 100.50 Mn |
| Dec 31, 2025 | 99.50 Mn |
| Sep 30, 2025 | 99.40 Mn |
| Jun 30, 2025 | 99.00 Mn |
| Mar 31, 2025 | 99.70 Mn |
| Dec 31, 2024 | 100.40 Mn |
| Sep 30, 2024 | 101.10 Mn |
| Jun 30, 2024 | 100.80 Mn |
| Mar 31, 2024 | 99.80 Mn |
| Dec 31, 2023 | 97.70 Mn |
| Sep 30, 2023 | 97.90 Mn |
| Jun 30, 2023 | 97.60 Mn |
| Mar 31, 2023 | 97.10 Mn |
| Dec 31, 2022 | 95.80 Mn |
| Sep 30, 2022 | 95.80 Mn |
| Jun 30, 2022 | 95.60 Mn |
| Mar 31, 2022 | 95.30 Mn |
| Dec 31, 2021 | 94.60 Mn |
| Sep 30, 2021 | 94.70 Mn |